Huang Huan, Zou Lingxiao, Zhang Aiqian, Zhao Xingping, Xu Dabao, Xue Min
Department of Obstetrics and Gynecology, Third Xiangya Hospital of Central South University, Changsha 410013, China.
Ann Transl Med. 2020 Feb;8(4):57. doi: 10.21037/atm.2020.01.77.
Management of intrauterine adhesions (IUAs) is challenging, mainly because there is no ideal method to prevent its recurrence. Recurrence of moderate to severe IUAs after conventional treatments entails a poorer prognosis in these patients. This study aimed to assess the safety and effectiveness of a patented intrauterine stent as a barrier in the treatment of recurrent IUAs with poor prognosis.
This was a retrospective, observational study of 13 women with IUAs, admitted to the Third Xiangya Hospital of Central South University from June 2018 to September 2019. After conventional treatments, moderate to severe adhesions were still evident. Then a patented intrauterine stent was used as a barrier to prevent the reformation of adhesions after hysteroscopic adhesiolysis (HA). All cases received a second-look hysteroscopy after 2-3 menstrual cycles. American Fertility Society (AFS) scores were noted for all cases. Menstrual pattern, recurrence of adhesions, and reproductive outcomes were also evaluated.
The mean number of previous HA of the 13 patients was 2.7, and mean AFS score after conventional treatments was still 8.7. Before the use of the stent, 46.2% of the patients had amenorrhea caused by IUAs. After using the intrauterine stent as a barrier, the mean AFS score was 1.7. The menstrual improvement rate was 100%, while the rate of resumption of normal menstrual volume was 53.8%. The second-look hysteroscopy revealed a correct position of the stents and no obvious recurrence of IUAs in all cases. After the removal of the stent, the patients were followed up for 2-13 months (mean: 7 months), and no amenorrhea was observed, the recurrence rate of IUAs was 25.0% and one patient got pregnant.
Even in the recurrent IUAs patients with very poor prognosis, the patented intrauterine stent has been proved to be very effective in preventing the recurrence of adhesions, on condition that its correct position inside the uterine cavity is achieved. Due to the extremely poor nature of the studied population, the recurrent rate of IUAs and pregnancy rate after the removal of the stent is still discouraging, although the improvement in menstruation is inspiring.
宫腔粘连(IUAs)的治疗具有挑战性,主要是因为没有理想的方法来预防其复发。常规治疗后中重度IUAs的复发会使这些患者的预后更差。本研究旨在评估一种专利宫内支架作为屏障在治疗预后不良的复发性IUAs中的安全性和有效性。
这是一项对2018年6月至2019年9月入住中南大学湘雅三医院的13例IUAs患者的回顾性观察研究。在常规治疗后,中重度粘连仍然明显。然后使用一种专利宫内支架作为屏障,以防止宫腔镜粘连松解术(HA)后粘连的重新形成。所有病例在2-3个月经周期后接受二次宫腔镜检查。记录所有病例的美国生育协会(AFS)评分。还评估了月经模式、粘连复发情况和生殖结局。
13例患者既往HA的平均次数为2.7次,常规治疗后的平均AFS评分为8.7分。在使用支架前,46.2%的患者因IUAs出现闭经。使用宫内支架作为屏障后,平均AFS评分为1.7分。月经改善率为100%,而月经血量恢复正常的比例为53.8%。二次宫腔镜检查显示所有病例中支架位置正确,且未发现IUAs明显复发。取出支架后,对患者进行了2-13个月(平均7个月)的随访,未观察到闭经,IUAs复发率为25.0%,1例患者怀孕。
即使在预后非常差的复发性IUAs患者中,已证明该专利宫内支架在实现其在宫腔内正确位置的情况下,对预防粘连复发非常有效。由于研究人群的情况极差,尽管月经改善令人鼓舞,但取出支架后的IUAs复发率和妊娠率仍然令人沮丧。